Periodic Reporting for period 1 - CHELALZ (Multitarget compounds with therapeutic potential against Alzheimer disease: Design and in vitro studies)

Aβ protein has been so far the main therapeutic target of choice to develop anti-Alzheimer drugs. However, therapies aiming to disrupt the amyloid cascade have reached Phase III clinical trials and have eventually failed. This is a key evidence of the multifactorial aetiology...